Navigation Links
Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
Date:8/26/2009

new' target='_new' href="http://www.octapharma.com/corporate/02_the_company/02_people/01_management_board/01_management_board.php" target="_new">Kim Bjornstrup. "Our first therapies were developed for the hemophilia community and today most hemophilia patient advocates say that inhibitor development is the greatest obstacle to effective treatment. Octapharma is focused on introducing innovative development strategies that will help improve patient quality of life by finding an effective treatment and developing products to overcome this obstacle."

The Octapharma-sponsored symposium "Prevention and Eradication of FVIII Inhibitors: Bridging Lab and Field Research" was chaired by David Lillicrap, M.D., Professor of Pathology and Molecular Medicine at Queen's University in Ontario, Canada, and Georges E. Rivard, M.D., Professor of Pediatrics at Universite de Montreal. The symposium provided an opportunity for discussing recent data supporting the use of von Willebrand factor (VWF)/FVIII concentrates for Immune Tolerance Induction (ITI) in hemophilia A patients with poor prognosis for a successful ITI outcome.

Presenters reviewed a balanced mix of clinical, preclinical and basic data on the role of the presence of VWF in FVIII concentrates and the clinical experience on prevention and eradication of FVIII inhibitors. In addition, the most recent prospective and retrospective clinical data obtained with different classes of FVIII concentrates used for ITI treatment were presented along with an update on the progress of the ongoing prospective study designed to further investigate the risk of FVIII inhibitor development in previously untreated patients with hemophilia.

"A growing body of clinical experience suggests that VWF-containing pdFVIII concentrates increase the likelihood of successful tolerization, particularly in patients with poor prognostic factors," said symposium presenter Wolfh
'/>"/>

SOURCE Octapharma AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
2. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
3. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
4. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
8. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
9. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
10. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe ... destination , today announced that it now offers the ... AirSense CPAPs are the first sleep apnea therapy devices ... simple and easy to track and share real-time data ... effectiveness of their CPAP therapy.  In addition, the internal ...
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... agreement that allows Kessler Foundation and New Jersey ... biomedical research, education and patient care programs has ... and chief executive officer of Kessler Foundation and ... Jersey Health Foundation. "The experience of ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... Leading academic and industry specialists ... discuss the challenges that could see R&D grind to a ... Selecting and screening the correct polymorphs and ensuring ... effective way has never been more vital. According to George ...
... Ontario, Canada, Oct. 27, 2011 Valeant Pharmaceuticals International, Inc. ... of 8,523,517 additional common shares of Afexa Life Sciences Inc. ... of the offer by its wholly-owned subsidiary 1625907 Alberta Ltd. ... of Afexa. As all of the conditions to the offer ...
Cached Medicine Technology:Pharma Industry Unites With Academia to Tackle Ongoing Problem 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 2Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization 3
(Date:9/30/2014)... emissions will reduce other harmful air pollution and ... new study released today. The research shows that, ... final Clean Power Plan, the power plant standards ... and hundreds of heart attacks in the United ... Co-benefits of Carbon Standards for Existing Power Plants, ...
(Date:9/30/2014)... University] Autism is no stranger to the children ... nation is access to clinical services, including reliable diagnosis ... for example, validated for use in Swahili, a major ... however, researchers at Brown University and the University of ... they implemented at two sites in the country and ...
(Date:9/30/2014)... Shrewsbury, NJ (PRWEB) September 30, 2014 ... health and wellness, is opening another new medical specialty ... group. IMA Cardiology will be located within ... Dr. Ziad Abbud and Dr. Isaac Tawfik of American ... Neptune, N.J. The new practice will offer Integrated Medicine ...
(Date:9/30/2014)... Glycodrive , one of the newest ... maximize lean, strong muscle growth with a proprietary blend ... has caught the attention of Shane Michaels, prompting an ... is to help the body use carbohydrates in a ... essential in the muscle-building process, and Glycodrive makes them ...
(Date:9/30/2014)... Angeles, CA (PRWEB) September 30, 2014 ... surgery providers in Turkey has gone up more than ... growth. The medical tourism company also reported total revenue ... October 2012. , The company’s professional strategy has allowed ... Turkey — ultimately designed for patient comfort and privacy ...
Breaking Medicine News(10 mins):Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... Be Celebrity Host of Show at Nassau Coliseum, NEW ... the first of its 2009 Concert Series -- a Valentine,s ... Research,Foundation., The show will be held on February 14th, ... on sale Monday, November 10th at 10am,through Ticketmaster.com or by ...
... at National Health Science Summit, DALLAS, Nov. ... prevention, today announced Dr. Valentin Fuster, director of,Mount ... Prevention Prize.,The Prize was presented to Dr. Fuster ... National Health Science Summit held on,November 7, 2008 ...
... 7 /PRNewswire-FirstCall/ - Transition Therapeutics Inc.,("Transition" or the "Company") ... call on Monday, November 10, 2008 at 4:30 P.M. ... Dr. Tony Cruz, Chairman,and Chief Executive Officer of the ... results for this period in a press release to,be ...
... valves years later , , FRIDAY, Nov. 7 (HealthDay News) -- ... fight obesity has been tied to heart value damage that ... new study reports. , The appetite suppressant fenfluramine has ... its links to heart damage. Thousands of lawsuits have been ...
... (NYSE: PER ) ( http://www.perotsystems.com ) today ... 2007, will fully transition its,name to Perot Systems, ... will now refer to the group as the ... the global information,technology provider,s deep healthcare solutions expertise ...
... and ST. PAUL, Minn., Nov. 7 Elementary,school ... bread products,are gradually introduced into their school lunches, ... grain breads are strongly recommended as part of ... eat them. For this study,researchers from the university,s ...
Cached Medicine News:Health News:Barry Manilow Brings Valentine's and Music to New York With Concert to Raise Funds for Breast Cancer Research 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 2Health News:U.S. Preventive Medicine(R) Awards Inaugural Global Prevention Prize to Dr. Valentin Fuster of Mount Sinai Heart 3Health News:Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST 2Health News:Banned Obesity Drug Tied to Heart Risks Long After Use 2Health News:Perot Systems Announces Name Change of JJWild 2Health News:Perot Systems Announces Name Change of JJWild 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: